These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 2127807)

  • 1. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
    Barrio JR; Huang SC; Melega WP; Yu DC; Hoffman JM; Schneider JS; Satyamurthy N; Mazziotta JC; Phelps ME
    J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA.
    Endres CJ; DeJesus OT; Uno H; Doudet DJ; Nickles JR; Holden JE
    Front Biosci; 2004 Jan; 9():505-12. PubMed ID: 14766386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-[18F]fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography.
    Melega WP; Hoffman JM; Schneider JS; Phelps ME; Barrio JR
    Brain Res; 1991 Mar; 543(2):271-6. PubMed ID: 1905578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
    Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
    Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography.
    Melega WP; Grafton ST; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
    J Cereb Blood Flow Metab; 1991 Nov; 11(6):890-7. PubMed ID: 1939384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
    Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
    J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
    Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
    J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans.
    Melega WP; Hoffman JM; Luxen A; Nissenson CH; Phelps ME; Barrio JR
    Life Sci; 1990; 47(2):149-57. PubMed ID: 2117691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of 6-[
    Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
    J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.
    Melega WP; Raleigh MJ; Stout DB; DeSalles AA; Cherry SR; Blurton-Jones M; Morton GG; Huang SC; Phelps ME
    Exp Neurol; 1996 Oct; 141(2):318-29. PubMed ID: 8812167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological imaging and the molecular basis of dopaminergic diseases.
    Barrio JR; Huang SC; Phelps ME
    Biochem Pharmacol; 1997 Aug; 54(3):341-8. PubMed ID: 9278092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
    Wahl L; Nahmias C
    J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
    Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
    J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys.
    Doudet DJ; Wyatt RJ; Cannon-Spoor E; Suddath R; McLellan CA; Cohen RM
    J Neural Transplant Plast; 1993; 4(1):27-38. PubMed ID: 7509198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
    Chiueh CC; Firnau G; Burns RS; Nahmias C; Chirakal R; Kopin IJ; Garnett ES
    Adv Neurol; 1987; 45():167-9. PubMed ID: 3103385
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
    Yee RE; Irwin I; Milonas C; Stout DB; Huang SC; Shoghi-Jadid K; Satyamurthy N; Delanney LE; Togasaki DM; Farahani KF; Delfani K; Janson AM; Phelps ME; Langston JW; Barrio JR
    Mov Disord; 2001 Sep; 16(5):838-48. PubMed ID: 11746613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
    Hoffman JM; Melega WP; Hawk TC; Grafton SC; Luxen A; Mahoney DK; Barrio JR; Huang SC; Mazziotta JC; Phelps ME
    J Nucl Med; 1992 Aug; 33(8):1472-7. PubMed ID: 1634937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.